Top of this page
Skip navigation, go straight to the content

Investors Overview

we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

image description

IR events

DateEvent details
26 November
Bryan, Garnier & Co Fireside Chatwith Emmanuel Caeymaex
29 November
JPMorgan Healthcare CEO Serieswith Jean-Christophe Tellier
01 December
Redburn CEO Conferencewith Jean-Christophe Tellier

2021 HY results

image description

2020 integrated report

image description

Upcoming report

DateEvent details
24 February
2021 Full-Year ResultsDetails closer to the date

Outlook 2021

Based on UCB’s current assessment of the COVID-19 pandemic, UCB remains confident in the fundamental underlying demand for its products and its prospects for long-term growth. UCB will continue to closely follow evolving COVID-19 pandemic diligently to assess potential near- and mid-term challenges.

The figures of the outlook 2021 as mentioned below were calculated on the same basis as the actual figures for 2020.

2021 revenue

€ 5.45 – 5.65 billion

thanks to current core product growth and new patient populations being served

Adjusted EBITDA 

27% - 28%

reflecting the high R&D and marketing & sales investment levels

Core earnings per share

€ 5.60 - € 6.10

based on an average of 189 million shares outstanding


Contact UCB IR team or a specific team member:




UCB IR app available on Apple Store

UCB IR app available on Google Play